This recommendation is largely based on (1) the ALBIOS trial which reported albumin may be associated with decreased mortality in the subgroup of patients with septic shock and hypoalbuminemia [54] and (2) the SAFE trial which showed no benefit to albumin in overall survival in critical illness but a decreased mortality in the subgroup of patients with sepsis [55]. The gene discussed is ALB; the disease is Sepsis.